Alterations in the serum glycome due to metastatic prostate cancer

Journal of Proteome Research

Volumn 6, Issue 5, 2007, Pages 1822-1832

  Kyselova, Zuzana ^a   Mechref, Yehia ^a   Al Bataineh, Mohammad M ^a   Dobrolecki, Lacey E ^b   Hickey, Robert J ^b   Vinson, Jake ^c   Sweeney, Christopher J ^b   Novotny, Milos V ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hoosier Oncology Group   (United States)

Author keywords

Biomarkers; Glycomics; Human blood serum; MALDI TOF; Mass spectrometry; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; GLYCAN DERIVATIVE; GLYCOPROTEIN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FUCOSYLATION; HUMAN; HUMAN CELL; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; METHYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN STRUCTURE; SOLID PHASE EXTRACTION;

AREA UNDER CURVE; BLOOD PROTEINS; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; GLYCOPROTEINS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; POLYSACCHARIDES; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34249277739     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr060664t     Document Type: Article

References (49)

1. American Cancer Society, Cancer Statistic 2006, available at www.cancer.org.
2. Diamandis, E. Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocrinol. Metab. 1998, 9, 310-316.
3. Brawer, M. K. Prostate-specific antigen: current status. CA - Cancer J. Clin. 1999, 49, 264-281.
4. Keetch, D. W.; Catalona, W. J.; Smith, D. S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J. Urol. 1994, 151, 1571-1574.
5. Mikolajczyk, S. D.; Catalona, W. J.; Evans, C. L.; Linton, H. J.; Millar, L. S.; Marker, K. M.; Katir, D.; Amirkhan, A.; Rittenhouse, H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin. Chem. 2004, 50, 1017-1025.
6. Adam, B. L.; Vlahou, A.; Semmes, O. J.; Wright, G. L., Jr. Proteomic approaches to biomarker discovery in prostate bladder cancers. Proteomics 2001, 1, 1264-1270.
7. Banez, L. L.; Srivastava, S.; Moul, J. W. Proteomics in prostate cancer. Curr. Opin. Urol. 2005, 15, 151-156.
8. Downes, M. R.; Byrne, J. C.; Dunn, M. J.; Fitzpatrick, J. M.; Watson, R. W.; Pennington, S. R. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer. A review. Biomarkers 2006, 11, 406-416.
9. Ornstein, D. K.; Tyson, D. R. Proteomics for the identification of new prostate cancer biomarkers. Urol. Oncol. 2006, 24, 231-236.
10. Shariat, S. F.; Canto, E. I.; Kattan, M. W.; Slawin, K. M. Beyond prostate-specific antigen: new serologic biomarkes for improved diagnosis and management of prostate cancer. Rev. Urol. 2004, 6, 58-72.
11. Dwek, M. V.; Lacey, H. A.; Leathem, A. J. Breast cancer progression is associated with a reduction in the diversity of sialylated and neutral oligosaccharides. Clin. Chim. Acta 1998, 271, 191-202.
12. Handerson, T.; Camp, R.; Harigopal, M.; Rimm, D.; Pawelek, J. Beta 1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin. Cancer Res. 2005, 11, 2969-2973.
13. Baldus, S. E.; Wienand, J. R.; Werner, J. P.; Landsberg, S.; Drebber, U.; Hanisch, F. G.; Dienes, H. P. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int. J. Oncol. 2005, 27, 1289-1297.
14. Alper, J. Glycobiology. Turning sweet on cancer. Science 2003, 301, 159-160.
15. Hakomori, S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)-lipid metabolism. Cancer Res. 1996, 56, 5309-5318.
16. Kobata, A. A retrospective and prospective view of glycopathology. Glycoconjugate J. 1998, 15, 323-331.
17. Tabares, G.; Radcliffe, C. M.; Barrabes, S.; Ramirez, M.; Aleixandre, R. N.; Hoesel, W.; Dwek, R. A.; Rudd, P. M.; Peracaula, R.; de Llorens, R. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006, 16, 132-145.
18. Wu, J. T.; Lyons, B. W.; Liu, G. H.; Wu, L. L. Production of milligram concentrations of free prostate-specific antigen (fPSA) from LNCaP cell culture: difference fPSA from LNCaP cell and seminal plasma. J. Clin. Lab. Anal. 1998, 12, 6-13.
19. Chandrasekaran, E. V.; Xue, J.; Xia, J.; Chawda, R.; Piskorz, C.; Locke, R. D.; Neelamegham, S.; Matta, K. L. Analysis of the specificity of sialyltransferases toward mucin core 2, globo, and related structures. Identification of the sialylation sequence and the effects of sulfate, fucose, methyl, and fluoro substituents of the carbohydrate chain in the biosynthesis of selectin and siglec ligands, and novel sialylation by cloned α2,3(O)sialyltransferase. Biochemistry 2005, 44, 15619-15635.
20. Tsuchiya, N.; Ohyama, C.; Habuchi, T. Tumor markers in prostate cancer-clinical significance and future prospect of prostate specific antigen (PSA). Gan To Kagaku Ryoho. 2005, 32, 275-280.
21. Kyselova, Z.; Mechref, Y.; Kang, P.; Goetz, J. A.; Dobrolecki, L. E.; Hickey, R. J.; Malkas, L. H.; Novotny, M. V. Breast cancer diagnosis/prognosis through quantitative measurements of serum glycan profiles. Clin. Chem., accepted.
22. Goetz J. A.; Mechref, Y; Kang, P.; Jeng, M.-H.; Novotny, M. V. Glycomic profiling of invasive and non-invasive breast cancer cells. Glycobiology, submitted for publication.
23. Kirmiz, C.; Li, B.; An, H. J.; Clowers, B. H.; Chew, H. K.; Lam, K. S.; Ferrige, A.; Alecio, R.; Borowsky, A. D.; Sulaimon, S.; Lebrilla, C. B.; Miyamoto, S. A serum glycomics approach to breast cancer biomarkers. Mol. Cell. Proteomics 2007, 6, 43-55.
24. An, H. J.; Miyamoto, S.; Lancaster, K. S.; Kirmiz, C.; Li, B.; Lam, K. S.; Leiserowitz, G. S.; Lebrilla, C. B. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J. Proteome Res. 2006, 5, 1626-1635.
25. Harvey, D. J. Matrix-assisted laser desorption/ionisation mass spectrometry of oligosaccharides and glycoconjugates. Review. J. Chromatogr., A 1996, 720, 429-446.
26. Harvey, D. J. Identification of protein-bound carbohydrates by mass spectrometry. Proteomics 2001, 1, 311-328.
27. Mechref, Y.; Novotny, M. V. Mass spectrometric mapping and sequencing of N-linked oligosaccharides derived from submicrogram amounts of glycoproteins. Anal. Chem. 1998, 70, 455-463.
28. Higai, K.; Shibukawa, K.; Muto, S.; Matsumoto, K. Targeted proteo-glycomics analysis of Sialyl Lewis X antigen expressing glycoproteins secreted by human hepatoma cell line. Anal. Sci. 2003, 19, 85-92.
29. Uematsu, R.; Furukawa, J.; Nakagawa, H.; Shinohara, Y.; Deguchi, K.; Monde, K.; Nishimura, S. High throughput quantitative glycomics and glycoform-focused proteomics of murine dermis and epidermis. Mol. Cell. Proteomics 2005, 4, 1977-1989.
30. Kang, P.; Mechref, Y.; Klouckova, I.; Novotny, M. V. Solid-phase permethylation of glycoconjugates for mass-spectrometric analysis. Rapid Commun. Mass Spectrom. 2005, 19, 3421-3428.
31. Canelle, L.; Bousquet, J.; Pionneau, C.; Hardouin, J.; Choquet-Kastylevsky, G.; Joubert-Caron, R.; Caron, M. A proteomic approach to investigate potential biomarkers directed against membrane-associated breast cancer proteins. Electrophoresis 2006, 27, 1609-1616.
32. Park, S. H.; Goo, J. M.; Jo, C.-H. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J. Radiol. 2004, 5, 11-18.
33. Wada, Y.; Azadi, P.;Costello, C. E.; Dell, A.; Dwek, R. A.; Geyer, H.; Geyer, R.; Kakehi, Kazuaki; Karlsson, N. G.; Kato, K.; Kawasaki, N.; Khoo, K.-H.; Kim, S.; Kondo, A.; Lattova, E. Mechref, Y.; Miyoshi, E.; Nakamura, K.; Narimatsu, H.; Novotny, M. V.; Packer, N. H.; Perreault, H. Peter-Katalinic, J.; Pohlentz, G. Reinhold, V. N.; Rudd, P. M.; Suzuki, A.; Taniguchi, N. Comparison of the methods for profiling glycoprotein glycans: HUPO HGPI (Human Proteome Organisation Human Disease Glycomics/Proteome Initiative) multi-institutional study. Glycobiology 2007, 17, 411-422.
34. Hotelling, H. Analysis of a complex of statistical variables into principal components. J. Educ. Psych. 1933, 24, 417-441.
35. Musumarra, G.; Barresi, V.; Condorelli, D. F.; Scire, S. A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol. Chem. 2003, 384, 321-327.
36. Rye, P. D.; Walker, R. A. Analysis of glycoproteins released from benign and malignant human breast: changes in size and fucosylation with malignancy. Eur. J. Cancer Clin. Oncol. 1989, 25, 65-72.
37. Hakim, A. A. A mechanism by which human breast carcinoma cells escape the host immune system. Neoplasma 1988, 35, 691-705.
38. Hanley, J. A.; McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143, 29-36.
39. Pepe, M. S.; Cai, T.; Longton, G. Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 2006, 62, 221-229.
40. Swets, J. A. Measuring the accuracy of diagnostic systems. Review. Science 1988, 240, 1285-1293.
41. Chandrasekaran, E. V.; Chawda, R.; Locke, R. D.; Piskorz, C. F.; Matta, K. L. Biosynthesis of the carbohydrate antigenic determinants, Globo H, blood group H, and Lewis b: a role for prostate cancer cell alphal,2-L- fucosyltransferase. Glycobiology 2002, 2, 153-162.
42. Mas, E.; Pasqualini, E.; Caillol, N.; El Battari, A.; Crotte, C.; Lombardo, D.; Sadoulet, M. O. Fucosyltransferase activities in human pancreatic tissue: comparative study between cancer tissues and established tumoral cell lines. Glycobiology 1998, 8, 605-613.
43. Izawa, M.; Kumamoto, K.; Mitsuoka, C.; Kanamori, C.; Kanamori, A.; Ohmori, K.; Ishida, H.; Nakamura, S.; Kurata-Miura, K.; Sasaki, K.; Nishi, T.; Kannagi, R. Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer. Cancer Res. 2000, 60, 1410-1416.
44. Mitsuoka, C.; Ohmori, K.; Kimura, N.; Kanamori, A.; Komba, S.; Ishida, H.; Kiso, M.; Kannagi, R. Regulation of selectin binding activity by cyclization of sialic acid moiety of carbohydrate ligands on human leukocytes. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 1597-1602.
45. Liu, F.; Zhang, Y.; Zhang, X. - Y.; Chen, H. - L. Transfection of the nm23-H1 gene into human hepatocarcinoma cell line inhibits the expression of sialyl Lewis X, a1,3 fucosyltransferase VII, and metastatic potential. J. Cancer Res. Clin. Oncol. 2002, 128, 189-196.
46. Saito, S.; Yamashita, S.; Endoh, M.; Yamato, T.; Hoshi, S.; Ohyama, C.; Watanabe, R.; Ito, A.; Satoh, M.; Wada, T.; Paulson, J. C.; Arai, Y.; Miyagi, T. Clinical significance of ST3Gal IV expression in human renal cell carcinoma. Oncol. Rep. 2002, 9, 1251-1255.
47. Peracaula, R.; Tabares, G.; Royle, L.; Harvey, D. J.; Dwek, R. A.; Rudd, P. M.; de Llorens, R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003, 13, 457-470.
48. Wuhrer, M.; Geyer, H.; von der Ohe, M.; Gerardy-Schahn, R.; Schachner, M.; Geyer, R. Localization of defined carbohydrate epitopes in bovine polysialylated NCAM. Biochemie 2003, 85, 207-218.
49. von Der Ohe, M.; Wheeler, S. F.; Wuhrer, M.; Harvey, D. J.; Liedtke, S.; Muhlenhoff, M.; Gerardy-Schahn, R.; Geyer, H.; Dwek, R. A.; Geyer, R.; Wing, D. R.; Schachner, M. Localization and characterization of polysialic acid-containing N-linked glycans from bovine NCAM. Glycobiology 2002, 12, 47-63.